On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early ...

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and ...

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon ...

AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...

AbbVie has shared promising top-line results from a phase 3 study of its investigational Parkinson’s disease (PD) candidate tavapadon in adults and said it is “on track” to submit a new drug ...

The trial results indicate that tavapadon, as a first-of-its-kind D1/D5 partial agonist, could be a potential monotherapy for Parkinson's disease, with plans to submit a New Drug Application (NDA ...

AbbVie (NYSE: NYSE:ABBV), a $311 billion market cap biotechnology giant with a "GOOD" financial health rating according to InvestingPro, today shared positive outcomes from its Phase 3 TEMPO-2 trial, ...